Adrenaline, cardiac arrest, and evidence based medicine

Timothy H Rainer, Colin E Robertson

Adrenaline has been used for over a century in the experimental resuscitation of animals following cardiac arrest.1 Its use in humans was proposed as early as 1896.2 It features as the primary pharmacological agent in the current European (ERC) and North American (AHA) guidelines for the management of cardiac arrest in adults and children.3,4 Despite these recommendations, there is doubt about the efficacy of adrenaline in this situation. “Evidence based medicine” is demanded increasingly by clinicians for current and future treatments.5 In this article we summarise the pharmacology and mechanisms of action of adrenaline, and review its use and value in cardiac arrest.

Endogenous catecholamine responses in cardiac arrest

Adrenaline is released from the adrenal medulla and sympathetic nerve terminals throughout the vascular system. Conditions such as trauma, hypotension, sepsis, and hypoglycaemia increase circulating concentrations of adrenaline and other catecholamines, producing increases in cardiac rate, contractility, and systemic vascular resistance.6 The highest endogenous concentrations of adrenaline occur in cardiac arrest.6 Despite these grossly elevated levels, their further augmentation appears to have beneficial haemodynamic effects.6

Adrenergic receptors have been found in many tissues including the heart, brain, and vascular system. Catecholamines such as adrenaline mediate their actions by stimulating these receptors, and two specific types have been demonstrated. Within these types, further differentiation into α1, α2, β1, β2, and β3 subtypes exist.10,11

Stimulation of α1 and α2 receptors causes vasoconstriction of arterial resistance vessels and venous capacitance vessels. In the beating heart, β1 receptor stimulation increases heart rate and contractility, and in the fibrillating heart may increase the frequency and amplitude of the fibrillating waveform.12 Stimulation of β2 receptors causes vascular and respiratory tract smooth muscle relaxation and hence vasodilatation and bronchodilatation, and may also reduce the threshold for defibrillation.13,14

Adrenaline shows α1, α2, β1, and β2 activity when given during cardiac arrest. The relative contributions made by stimulation of these receptors and their subtypes is important and will influence factors such as coronary and cerebral perfusion. The effect of stimulation of these receptors depends upon their number and tissue density, functional state (“up- and downregulation”), and accessibility to the agent.1

Mechanisms producing perfusion during cardiopulmonary resuscitation

Closed chest cardiopulmonary resuscitation (CPR), at best, produces approximately one third of the normal cardiac output of the spontaneously beating heart.15 Thus a primary goal of CPR is to produce a return of spontaneous circulation. In its absence, and hopefully pending its return, efforts to maximise cardiac output during CPR are crucial to improving myocardial and cerebral perfusion.

Myocardial blood flow, and hence the heart’s viability, is related to the coronary perfusion pressure. This is the difference between aortic diastolic pressure and the right atrial pressure. In animals and humans, coronary perfusion pressure levels correlate well with successful defibrillation and return of spontaneous circulation.10,16 During spontaneous circulation there are differences in the flow between the epicardial and intramyocardial arteries. At higher atrial pressures the phasic differences in coronary blood flow are small. At normal or lower arterial pressures, antegrade flow persists through the larger epicardial vessels during systole, although there is retrograde flow through the intramyocardial vessels preventing coronary filling. Perfusion of the intramyocardial vessels therefore occurs during diastole at lower arterial pressures. At higher pressures it continues during systole.17 In cardiac arrest, the difference between aortic diastolic pressure and right atrial pressure is still important, but the mechanisms producing this differ from those of spontaneous circulation. Coronary perfusion occurs during the relaxation phase of chest compression in CPR rather than diastole as in the beating heart. During CPR, right atrial pressure is relatively constant; hence myocardial perfusion reflects changes in aortic diastolic pressure.

Cerebral function and preservation depend on cerebral perfusion. Since the brain’s autoregulatory ability is poor, especially in states of low systemic flow such as are found in cardiac arrest, cerebral perfusion is directly

The Directorate of Accident and Emergency Medicine, Royal Infirmary of Edinburgh, Lauriston Place, Edinburgh EH3 9YW
T H Rainer
C E Robertson
Correspondence to: Dr Timothy H Rainer (senior registrar)
Accepted for publication 2 April 1996
Key terms: adrenaline; cardiac arrest; cardiopulmonary resuscitation; outcomes
Adrenaline, cardiac arrest, and evidence based medicine

influenced by cardiac output. Cerebral perfusion depends upon the gradient between arterial and venous pressures and will also be affected by factors influencing intracranial pressure. Thus, in contrast to the heart, cerebral perfusion occurs during the compression or “systolic” phase of the CPR cycle. Furthermore, the longer the downtime from onset of cardiac arrest to initiation of bystander CPR the poorer the cerebral perfusion.

**Haemodynamic effects in animal studies**

Since controlled human studies investigating the mechanisms of action of adrenaline in cardiac arrest are impossible, our knowledge is principally derived from animal models. From these studies it is clear that adrenaline improves the global haemodynamic state in cardiac arrest by increasing systemic vascular resistance (thus increasing aortic diastolic pressure) and altering patterns of regional blood flow, directing blood preferentially to the heart and brain. These actions are dose dependent. With increasing doses, parallel increases can be demonstrated in aortic diastolic pressure, myocardial blood flow and oxygen consumption, and cerebral cortical and brainstem flow. These actions are mirrored by improved rates of outcome parameters such as return of spontaneous circulation and survival.

The efficacy of adrenaline may be further affected by its method of administration. It may be introduced intravenously through a peripheral or central vein, by intracardiac injection, or endobronchially, and this may be followed by a method of dispersion such as a bolus of fluid or rapid repeated ventilations. When adrenaline is given exogenously higher arterial concentrations are achieved than can be attained through endogenous production, and when it is given early after the induction of cardiac arrest it has an impact on immediate resuscitability.

The extrapolation of animal data to the human clinical situation is, however, fraught with problems. Humans have unique physiological, anatomical, and receptor characteristics, and experimental animals are not usually affected by the principal disease process that leads to adult human cardiac arrest – ischaemic heart disease.

**Haemodynamic effects in human studies**

Adrenaline increases systemic pressures achieved during CPR in a dose dependent fashion, and as a result improves coronary perfusion pressure. However, potentially deleterious haemodynamic effects include coronary vasoconstriction and postresuscitation arterial hypertension. Adrenaline is thought to augment cerebral blood flow by shunting blood from non-essential organs and increasing carotid arterial pressure, with redistribution towards the cerebrum. It may also improve cerebral perfusion by resisting the tendency of the intrathoracic portion of the carotid artery to collapse.

**Adrenaline and electrical responses**

In cardiac arrest, electrical activity may broadly be divided into three groups: ventricular fibrillation/tachycardia (VF/VT), asystole, and electromechanical dissociation (EMD). Without treatment and with the passage of time, the VF waveform decreases in amplitude and frequency. These changes are accompanied by reduction in the probability of successful defibrillation and relate to the depletion of myocardial high energy phosphate stores.

ANIMAL AND HUMAN STUDIES

Adrenaline increases the frequency and amplitude of the VF waveform by β2 receptor stimulation. However, this has not been shown to improve the chances of successful defibrillation, either in healthy hearts or in those following coronary occlusion. Few human studies have documented changes in the amplitude and frequency of the fibrillatory waveform either with different doses of adrenaline or placebo, although marked coarsening in VF followed the administration of high dose adrenaline in one patient.

**Adrenaline and CPR outcome**

In the past, comparison and evaluation of outcomes from published reports have been difficult because of a lack of standardisation in the reporting of results.

**ANIMAL STUDIES**

Most animal studies concentrate upon the haemodynamic effects of adrenaline in cardiac arrest. Outcomes are usually expressed as survival for minutes or hours. An improvement in these indices has been demonstrated following the administration of adrenaline. However, few studies report on survival to 24 hours or longer. Thus it is uncertain if the improvement in haemodynamic status is matched to long term survival.

**HUMAN STUDIES – STANDARD DOSE V HIGH DOSE**

If improved haemodynamics lead to more favourable outcomes this would be expected to be manifest by a dose-response effect. However, demonstrating this effect has proved difficult. Early anecdotal reports using “high” doses (5–10 mg; HD) of adrenaline suggested beneficial effects on survival and led various groups to investigate the comparative effect of different doses of adrenaline upon outcome.

The first prospective, randomised trials compared HD and standard dose (SD) adrenaline and showed an improvement in resuscitation rates, but the number of patients studied was small, and the power of the studies limited.

Three large prospective randomised North American trials have been published. One (prehospital) study showed a significant improvement in early outcome measures and a non-significant trend towards greater discharge rates with high dose adrenaline. However, trends in cerebral performance categories were worse with the higher dose.
There was no significant difference in the duration of hospital or critical care unit stays. The other two studies did not show any significant improvement in return of spontaneous circulation, resuscitation rates, admission or discharge rates, or neurological outcome with high dose adrenaline.35 36

A recent French trial confirmed no improvement in return of spontaneous circulation or admission rates and at six months could show no significant difference in survival between HD and SD.37 While neither adverse cardiac nor neurological effects were noted, the number of long term survivors was very small.

HUMAN STUDIES – STANDARD DOSE V PLACEBO/NO DOSE

Few studies have compared adrenaline versus placebo. Most were non-randomised, uncontrolled studies – and few have looked at adrenaline as the main study intervention.38–42 Some look only at groups with a recognised poor prognosis, that is, asystole34 or electromechanical dissociation.42 Only one study recorded return of spontaneous circulation as an outcome variable.39 In this uncontrolled trial a better outcome was found in those patients who did not receive adrenaline.

Of the in-hospital studies, none was controlled and none found improvement in discharge rates associated with adrenaline.38–41 Two showed a significantly better outcome following placebo/no drug.39 41

The data from prehospital studies42–44 comparing adrenaline and placebo are even scantier, but one study showed a trend towards improved survival in those not receiving adrenaline. Although all these studies are prospective, the study with the greatest power was not randomised and investigated a group with a poor prognosis.44

While the methodologies of most of these studies are not ideal – retrospective or descriptive, with no predetermined control or randomisation – the evidence to date suggests that, if anything, adrenaline has a detrimental effect on outcome.

Conclusion: where do we go from here?

Despite the fact that the use of adrenaline in cardiac arrest has been hallowed by time, and that it is the drug of choice in both ERC and AHA guidelines, there is a lack of evidence that it improves outcome. High dose adrenaline provides no additional benefit over standard dose regimens, and pending the results of definitive studies on standard dose and placebo a healthy scepticism is warranted. The first prospective, randomised, double blind controlled trial comparing adrenaline with placebo has not yet been published. The study numbers were small and there were no differences in discharge survival. If there are any benefits of adrenaline on overall survival following cardiac arrest they appear to be slight, although it is possible that in certain subgroups of patients the benefit may be more marked. In the meantime the importance of basic life support and prompt defibrillation in the treatment of cardiac arrest cannot be over emphasised.

Summary

In this article we review the evidence supporting the clinical application of adrenaline in cardiopulmonary arrest, and summarise the receptor effects of catecholamines and the basic principles producing perfusion during CPR. Animal and human studies show that in cardiac arrest, adrenaline has positive haemodynamic effects, increasing systemic pressures, myocardial perfusion, and cerebral directed flow. The problems extrapolating from animal to human data are highlighted. Studies showing improvements in short term survival outcomes with high dose regimens have not been confirmed by other large prospective randomised trials. There is no evidence that high doses of adrenaline improve survival to hospital discharge. Most studies comparing adrenaline with placebo have been non-randomised and uncontrolled, with major methodological problems. Conclusions are difficult, but if anything adrenaline is associated with poorer outcomes.

2nd AUSTRALIAN INTERNATIONAL EMERGENCY NURSING CONFERENCE

"Proud of Our Past . . . Confident of Our Future"

8, 9, 10 & 11 October 1996,
The Hilton Hotel, Sydney, Australia

For Conference brochure contact:
Conference Secretariat, Emergency Nurses Association of NSW
PO Box 953, Parramatta, NSW, Australia 2124
Tel/fax: + 61 2 688 4937 or + 61 47 33 2400